scholarly journals NADPH Oxidase and Epidermal Growth Factor Receptor Are Promising Targets of Phytochemicals for Ultraviolet-Induced Skin Carcinogenesis

Antioxidants ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1909
Author(s):  
Min Jeong Kim ◽  
Su Jeong Ha ◽  
Bo Ram So ◽  
Chang-Kil Kim ◽  
Kyung-Min Kim ◽  
...  

The skin acts as the primary defense organ that protects the body from the external environment. Skin cancer is one of the most common cancers in the world. Skin carcinogenesis is usually caused by cell degeneration due to exposure to ultraviolet (UV) radiation, which causes changes in various signaling networks, disrupting the homeostasis of single skin cells. In this review, we summarize the roles of nicotinamide adenine dinucleotide phosphate oxidase (NOX) and epidermal growth factor receptor (EGFR) in UV-induced skin carcinogenesis. Furthermore, we describe the crosstalk that exists between NOX, EGFR, and protein tyrosine phosphatase κ and its oncogenic downstream signaling pathways. Chemoprevention is the use of chemical compounds to recover the healthy status of the skin or delay cancer development. Current evidence from in vitro and in vivo studies on chemopreventive phytochemicals that target NOX, EGFR, or both, as major regulators of skin carcinogenesis will also be discussed.

2004 ◽  
Vol 64 (7) ◽  
pp. 2382-2389 ◽  
Author(s):  
Keith Syson Chan ◽  
Steve Carbajal ◽  
Kaoru Kiguchi ◽  
John Clifford ◽  
Shigetoshi Sano ◽  
...  

2020 ◽  
Author(s):  
Xin Wang ◽  
Xiaoli Zhu ◽  
Jieya Zou ◽  
Xia Zhang ◽  
Xuemei Wu ◽  
...  

Abstract Background: Trastuzumab can significantly prolong the survival of patients with positive human epidermal growth factor receptor-2 breast cancer. Until now, trastuzumab has been used by millions of people, and trastuzumab-induced thrombocytopenia is rare. There is no report of acute grade 4 thrombocytopenia after weekly trastuzumab therapy. We report a breast cancer patient with severe thrombocytopenia due to trastuzumab (8mg/Kg) who experienced a recurrence of severe thrombocytopenia after attempting weekly trastuzumab therapy (4mg/Kg). Case presentation:A 52-year-old woman with positive human epidermal growth factor receptor-2 breast cancer developed acicular rash with dense skin all over the body and gingival bleeding within 24 hours of trastuzumab infusion (8mg/Kg) and was confirmed to have severe thrombocytopenia, which was quickly recovered after high-dose corticosteroid pulse therapy. When the platelet count recovered, we tried weekly trastuzumab therapy (4mg/kg), Unfortunately, thrombocytopenia recurred within 24 hours. No third trastuzumab treatment was attempted. Conclusion: We are the first report to try weekly trastuzumab therapy after thrombocytopenia induced by first trastuzumab. The patient showed that reducing the dose of trastuzumab was ineffective in preventing trastuzumab-induced thrombocytopenia.


2013 ◽  
Vol 13 (10) ◽  
pp. 1207-1218 ◽  
Author(s):  
Raffaele Costanzo ◽  
Agnese Montanino ◽  
Massimo Di Maio ◽  
Maria Carmela Piccirillo ◽  
Claudia Sandomenico ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document